Expression pattern of prokineticin 1 and its receptors in bovine ovaries during the estrous cycle: involvement in corpus luteum regression and follicular atresia.
Prokineticin 1 (PROK1), also termed endocrine gland-derived vascular endothelial growth factor (endocrine gland-derived VEGF), is a newly identified protein assigned with diverse biologic functions. It binds two homologous G protein-coupled receptors, PROKR1 and PROKR2. To better understand the roles of PROK1 and its receptors in ovarian function, their expression was determined in follicles and corpora lutea (CLs) at different developmental stages. PROK1 mRNA levels were low at early luteal stage and midluteal stage, but increased sharply during natural or induced luteolysis. High PROK1 mRNA levels also were found in atretic follicles. This profile of PROK1 expression was opposite to that of the well-established angiogenic factor VEGF. Of the two receptor-type expressions, PROKR1 but not PROKR2 was correlated positively with its ligand. Immunohistochemical staining revealed that PROK1 was located mainly within the muscular layer of arterioles, and during regression it also was localized to macrophages and steroidogenic cells. The expression pattern of ITGB2 mRNA, a leukocyte cell marker, overlapped that of PROK1, thus suggesting that leukocyte infiltration may explain the elevated expression of PROK1 in atretic follicles and regressing CL. Indeed, flow cytometry analyses showed that nearly all beta-2 integrin chain (ITGB2)-positive cells also were stained with anti-PROK1 and that significantly more ITGB2/PROK1 double-stained cells were present in degenerating follicles and CL. Furthermore, when challenged in vitro with PROK1, adherent, mononuclear cell numbers and TNF levels were elevated, indicating that PROK1 triggers monocyte activation. Together, these data suggest that PROK1, acting via PROKR1, may be involved in the recruitment of monocytes to regressing CL and atretic follicles and their consequent activation therein.
Kisliouk
Tatiana
T
Départment des Sciences du Vivant sud, Commissariat à l'Energie Atomique de Grenoble, 38000 Grenoble, France.
Friedman
Aharon
A
Klipper
Eyal
E
Zhou
Qun-Yong
QY
Schams
Dieter
D
Alfaidy
Nadia
N
Meidan
Rina
R
D000818:Animals; D002417:Cattle; D002452:Cell Count; D002518:Ceramides / Q000378:metabolism; D002786:Cholesterol Side-Chain Cleavage Enzyme / Q000096:biosynthesis / Q000235:genetics; D003338:Corpus Luteum / Q000254:growth & development*; D015237:Dinoprost / Q000096:biosynthesis / Q000235:genetics; D004926:Escherichia coli / Q000378:metabolism; D030762:Estrous Cycle / Q000378:metabolism*; D005260:Female; D005434:Flow Cytometry; D005496:Follicular Atresia / Q000502:physiology*; D007150:Immunohistochemistry; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism; D010053:Ovary / Q000378:metabolism*; D043562:Receptors, G-Protein-Coupled / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis; D042662:Vascular Endothelial Growth Factor, Endocrine-Gland-Derived / Q000096:biosynthesis* / Q000235:genetics*
D002518:Ceramides; D043562:Receptors, G-Protein-Coupled; D042461:Vascular Endothelial Growth Factor A; D042662:Vascular Endothelial Growth Factor, Endocrine-Gland-Derived; D015237:Dinoprost; D002786:Cholesterol Side-Chain Cleavage Enzyme